Global Epilepsy Market – Industry Trends and Forecast to 2030

Epilepsy Market Analysis and Size

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures. Seizures occur due to abnormal electrical activity in the brain, which leads to temporary disruptions in normal brain function. Epilepsy can affect people of all ages, and its causes can vary. If someone experiences recurring seizures, they should seek medical attention. A diagnosis of epilepsy typically involves a thorough medical history review, neurological examination, and various tests, such as electroencephalogram (EEG), brain imaging (MRI, CT scan), and blood tests. These help identify the underlying cause and determine the most appropriate treatment.

Data Bridge Market Research analyses that the epilepsy market which was USD 2,280.00 million in 2022, would rocket up to USD 3,888.27 million by 2030, and is expected to undergo a CAGR of 6.9% during the forecast period. Epilepsy drug resistant/intractable epilepsy dominates the product type segment of the Epilepsy market owing to the increasing prevalence of epilepsy. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Epilepsy Market Scope and Segmentation

Market Definition

The term "epilepsy" describes a long-term neurological condition that results in frequent, unjustified seizures. A person with epilepsy frequently experiences seizures that have no known cause. The actual origins of these seizures are unknown, but some stressful event or a prior brain injury may bring them. The disorder often affects both adults and children, however, the danger of infection is higher in the elderly population.

Epilepsy Market Dynamics

Drivers

• Increasing prevalence of epilepsy

Epilepsy is a common neurological disorder, and its prevalence is increasing globally. The growing population, aging demographics, and improved diagnostic capabilities contribute to the rising number of epilepsy cases, thereby driving the demand for epilepsy treatment and management.

• Drug development and innovation

Pharmaceutical companies continue to invest in research and development to discover new anti-epileptic drugs (AEDs) with improved efficacy, safety, and tolerability profiles. The introduction of novel therapeutics and treatment options expands the market and provides better choices for patients with epilepsy.

• Increasing demand for anti-epileptic drugs (AEDs)

AEDs are the primary treatment for epilepsy. The growing patient population and the need for long-term medication drive the demand for AEDs, leading to market growth. Additionally, the development of newer AEDs with improved efficacy and fewer side effects provides opportunities for market expansion.

• Advancements in brain stimulation therapies

Brain stimulation therapies, such as vagus nerve stimulation (VNS) and responsive neurostimulation (RNS), have shown efficacy in reducing seizure frequency and improving patients' quality of life. Ongoing technological advancements and the development of innovative stimulation devices drive market growth in this segment.

Opportunities

• Pediatric epilepsy treatment market

Pediatric epilepsy represents a significant segment of the overall epilepsy market. The rising prevalence of epilepsy in children and the development of pediatric-specific AEDs fuel market growth. Additionally, initiatives focused on improving pediatric epilepsy care and advancing research contribute to market expansion.

• Awareness campaigns and patient advocacy

Various organizations and advocacy groups dedicated to epilepsy awareness and support play a crucial role in driving market growth. These campaigns aim to reduce the stigma associated with epilepsy, improve early detection, and ensure access to proper treatment and support services.

Restraints/Challenges

• Side effects of antiepileptic drugs (AEDs)

Although AEDs are essential in managing epilepsy, they can have significant side effects, such as drowsiness, dizziness, cognitive impairments, and mood changes. These side effects can impact patient compliance with medication regimens and lead to treatment discontinuation, affecting the overall market growth.

• Limited efficacy of current treatments

Despite the availability of a wide range of AEDs, a considerable number of patients with epilepsy experience inadequate seizure control or drug resistance. This limitation in treatment efficacy underscores the need for more effective therapeutic options and personalized treatment approaches, which may impact the market growth.

This epilepsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the epilepsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In March 2022, FDA has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. This is the first treatment for seizures associated with CDD and the first treatment specifically for CDD.
• In January 2021, Glenmark Pharma announced the launch of the anti-epileptic drug Rufinamide tablets in the US market. Glenmark Pharmaceuticals Ltd has launched Rufinamide tablets USP in 200 mg and 400 mg, the company said in a regulatory filing.

Global Epilepsy Market Scope

The epilepsy market is segmented on the basis of condition, drug, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Condition

• Epilepsy Drug Resistant/Intractable Epilepsy
• Others

Drug

• First-Generation
• Second-Generation
• Third-Generation

Distribution Channel

• Hospitals
•  Clinics
• Retail Pharmacies
• Online Pharmacies

End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers

Epilepsy Market Regional Analysis/Insights

The epilepsy market is analyzed, and market size insights and trends are provided by country, condition, drug, distribution channel, and end user as referenced above.

The countries covered in the epilepsy market report are U.S., Canada and Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe in Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America dominates the epilepsy market because of the rising prevalence of epilepsy in region, growing investment in healthcare infrastructure is also boosting the growth of the market.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The epilepsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for epilepsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the epilepsy market. The data is available for historic period 2010-2020.

Competitive Landscape and Epilepsy Market Share Analysis

The epilepsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epilepsy market.

Some of the major players operating in the epilepsy market are:

• Pfizer Inc. (U.S.)
• Novartis AG (Germany)
• Abbott (U.S.)
• Neurelis Inc. (U.S.)
• GSK plc (U.K.)
• Johnson & Johnson Services Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (U.S.)
• Sumitomo Dainippon Pharma Co. Ltd (Japan)
• Bausch Health Companies Inc. (Canada)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• UCB S.A. (China)
• Marinus Pharmaceuticals Inc. (U.S.)
• Eisai Co. Ltd (Japan)
• H. Lundbeck A/S (Denmark)
• Supernus Pharmaceuticals Inc (U.S.)
• DAIICHI SANKYO COMPANY LIMITED (Japan)

SKU-44858